IDH1/2 somatic mutations are associated with lower normalized mean diffusion kurtosis [2], increased ZEB1 expression in lower-grade gliomas [3], preoperative seizures in gliomas [4], CpG methylator phenotype (CIMP), global hypermethylation, younger age, secondary glioblastoma, and increased overall survival [5, 6]. The gene discussed is IDH1; the disease is glioblastoma.